Switch To Branded denied as not FDA-approved for this use by Humana?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for switch to branded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Switch To Branded
## Why Humana Says the Branded Drug Is Not FDA-Approved (and What That Actually Means for Your Appeal)
A "not FDA-approved" denial in the context of a switch to a branded medication most commonly arises in one of two scenarios: (1) the prescriber is requesting the branded drug for an indication that is not listed on the FDA-approved label (an "off-label" use), or (2) there is a documentation or routing error where Humana matched the claim against the wrong product or indication. Before proceeding with a full appeal, confirm with your prescriber which scenario applies.
## Why This Denial Is Appealable
If the use is on-label: The denial is factually incorrect and should be correctable with documentation. Submit the FDA prescribing label showing approval for your specific diagnosis and request an expedited internal review.
If the use is off-label: Off-label prescribing is legal and common. Many plans — including Humana — are required to cover off-label uses that are supported by established medical compendia or professional society guidelines. Your appeal should demonstrate that the use meets Humana's coverage standard for off-label drugs (usually compendia or guideline citation).
Your federal appeal rights: - Internal appeal (ACA §2719 / ERISA §503): File within 180 days. The plan must explain the specific basis for the not-approved finding. - External review: An IRO applies objective clinical standards. The window is generally up to four months from final internal denial. - Expedited review (72 hours): Available when delay poses serious health risk.
## What to Gather
- FDA prescribing label for the branded drug: Download directly from the FDA's Drugs@FDA database. Highlight the indication(s) listed.
- If off-label: Reference (not quoted statistics) to the applicable professional society guideline or recognized medical compendium (e.g., NCCN, Micromedex, DrugDex) supporting this use. Ask your prescriber to identify the compendia reference.
- Prescriber medical-necessity letter: Should state the specific indication being treated, confirm whether it is on-label or off-label, and cite the applicable compendia/guideline organization if off-label.
- Humana's off-label coverage policy: Request it by name. Note which compendia or guidelines Humana recognizes for off-label coverage.
## Criteria-Mapping Structure
| Humana's "Not Approved" Basis | Your Rebuttal | |---|---| | Indication not on FDA label | FDA label excerpt showing approved indication OR compendia/guideline support for off-label use | | [Specific policy criterion] | Prescriber letter directly addressing each criterion | | Compendia not cited | Relevant compendia reference identified by prescriber |
Your appeal letter should open by precisely identifying the indication, then attaching the FDA label. If the use is off-label, systematically show that Humana's own off-label policy criteria are met. External review is particularly effective here because IROs evaluate clinical evidence and compendia support independently.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →